We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Role of ST2 in Acute Pancreatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01315613
Recruitment Status : Completed
First Posted : March 15, 2011
Last Update Posted : March 15, 2011
Information provided by:
Erasme University Hospital

Brief Summary:
Acute pancreatitis is characterized by an inflammatory storm which regulatory pathways are not well known. The IL-1 cytokine family is activated early during acute pancreatitis and secretion of alarmins is speculated during pancreatic necrosis. IL-33 is a member of the IL-1 family, it can act as an alarmin and its receptor, ST2, is known to sequester MyD88 which might regulate the acute pancreatitis inflammatory storm. The aim of this study is to investigate ST2 pathway in human acute pancreatitis and in murine experimental models of acute pancreatitis.

Condition or disease
Acute Pancreatitis

Study Type : Observational
Actual Enrollment : 44 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Study of ST2-IL-33 Pathway in Acute Pancreatitis
Study Start Date : January 2005
Primary Completion Date : September 2008
Estimated Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis
U.S. FDA Resources

Acute pancreatitis
Patients admitted in our institution for an episode of acute pancreatitis

Primary Outcome Measures :
  1. Concentration of soluble ST2 in serum [ Time Frame: Within 30 days after onset of acute pancreatitis ]
    Concentration of soluble ST2 will be assessed in the serum of patient with an episode of acute pancreatitis, on the day of admission to the hospital as well as 24h, 48h, 7 days and 30 days later.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients of Erasme University Hospital

Inclusion Criteria:

  • Time to take blood sample less than 24h after the onset of symptoms of AP
  • Two of the following: typical pain, amylase and lipase concentrations more than 3x the upper normal limit, compatible modifications on imaging techniques

Exclusion Criteria:

  • Chronic pancreatitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01315613

Erasme Hospital
Brussels, Belgium, 1070
Sponsors and Collaborators
Erasme University Hospital
Principal Investigator: Romy Ouziel, MD Erasme Hospital

Responsible Party: Romy Ouziel,, Erasme Hospital
ClinicalTrials.gov Identifier: NCT01315613     History of Changes
Other Study ID Numbers: RO-ST2
First Posted: March 15, 2011    Key Record Dates
Last Update Posted: March 15, 2011
Last Verified: September 2008

Additional relevant MeSH terms:
Pancreatic Diseases
Digestive System Diseases